{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:34:15Z","timestamp":1789533255667,"version":"build-2803163510"},"reference-count":248,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mattioli 1885 srl on behalf of AstraZeneca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The treatment landscape for CLL has undergone a profound transformation with the advent of targeted agents (TAs) like Bruton\u2019s Tyrosine Kinase inhibitors (BTKis) and BCL-2 inhibitors (BCL-2is). These agents target crucial cellular pathways in CLL, offering superior efficacy over traditional chemo-immunotherapy, which has led to improved progression-free and overall survival rates. This advancement promises enhanced disease control and potentially normal life expectancy for many patients. However, the journey is not without challenges, as these TAs are associated with a range of adverse events (AEs) that can impact treatment efficacy and patient quality of life. This review focuses on detailing the various AEs related to TA management in CLL, evaluating their frequency and clinical impact. The aim is to present a comprehensive guide to the effective management of these AEs, ensuring optimal tolerability and efficacy of TAs. By reviewing the existing literature and consolidating findings, we provide insights into AE management, which is crucial for maximizing patient outcomes in CLL therapy.<\/jats:p>","DOI":"10.3390\/cancers16111996","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T06:59:04Z","timestamp":1716533944000},"page":"1996","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9122-4258","authenticated-orcid":false,"given":"Andrea","family":"Galitzia","sequence":"first","affiliation":[{"name":"Hematology and Stem Cell Transplantation Unit, Ospedale San Francesco, 08100 Nuoro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Maccaferri","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Oncology and Hematology, A.O.U of Modena, Policlinico, 41125 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2425-9474","authenticated-orcid":false,"given":"Francesca Romana","family":"Mauro","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9792-9542","authenticated-orcid":false,"given":"Roberta","family":"Murru","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, ARNAS G. Brotzu, 09134 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-6878","authenticated-orcid":false,"given":"Roberto","family":"Marasca","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Oncology and Hematology, A.O.U of Modena, Policlinico, 41125 Modena, Italy"},{"name":"Department of Medical and Surgical Sciences, Section of Hematology, University of Modena and Reggio Emilia, 41121 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic Lymphocytic Leukemia: 2022 Update on Diagnostic and Therapeutic Procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.3145","article-title":"First Line Therapy of CLL","volume":"41","author":"Hallek","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ajh.27182","article-title":"Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Age > 65 Relative to Age- and Sex-matched Population","volume":"99","author":"Molica","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s Tyrosine Kinase in B Cells and Malignancies","volume":"17","author":"Dammeijer","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s Tyrosine Kinase in B Cell Malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2018-99-109973","article-title":"Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies","volume":"132","author":"Kaptein","year":"2018","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-Year Follow-up from RESONATE-2: First-Line Ibrutinib Treatment for Patients with Chronic Lymphocytic Leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/bjh.19276","article-title":"Mortality Trends of Chronic Lymphocytic Leukaemia in the United States with the Emergence of Targeted Therapy","volume":"204","author":"Tan","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000534730","article-title":"Frontline Therapy in Chronic Lymphocytic Leukemia","volume":"147","author":"Albiol","year":"2024","journal-title":"Acta Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic Lymphocytic Leukaemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_13","unstructured":"Mu\u00f1oz, J.L., Chavez, J.C., Sotomayor, E.M., Barrientos, J.C., and Castillo, J.J. (2023). Interdisciplinary Cancer Research, Springer International Publishing."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-019-00512-0","article-title":"Targeting BTK in CLL: Beyond Ibrutinib","volume":"14","author":"Bond","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in Relapsed or Refractory B-Cell Malignancies (BRUIN): A Phase 1\/2 Study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3109\/10428194.2013.777837","article-title":"Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765)","volume":"54","author":"Burger","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"720704","DOI":"10.3389\/fonc.2021.720704","article-title":"Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice","volume":"11","author":"Brown","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1182\/bloodadvances.2023009739","article-title":"Real-World Comparative Effectiveness of Acalabrutinib and Ibrutinib in Patients with Chronic Lymphocytic Leukemia","volume":"7","author":"Roeker","year":"2023","journal-title":"Blood Adv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib Monotherapy in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia: Updated Phase 2 Results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and Safety in a 4-Year Follow-up of the ELEVATE-TN Study Comparing Acalabrutinib with or without Obinutuzumab versus Obinutuzumab plus Chlorambucil in Treatment-Na\u00efve Chronic Lymphocytic Leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 Study of the Selective BTK Inhibitor Zanubrutinib in B-Cell Malignancies and Safety and Efficacy Evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/JCO.22.00510","article-title":"Zanubrutinib Versus Ibrutinib in Relapsed\/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial","volume":"41","author":"Hillmen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.amjcard.2015.01.540","article-title":"Relation between Cancer and Atrial Fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study)","volume":"115","author":"Lakoski","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular Toxicities Associated with Ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaccao.2020.11.016","article-title":"How to Manage Atrial Fibrillation Secondary to Ibrutinib","volume":"3","author":"Essa","year":"2021","journal-title":"JACC Cardio Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial Fibrillation in Patients with Chronic Lymphocytic Leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-Term Follow-up of the RESONATE Phase 3 Trial of Ibrutinib vs. Ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-Term Efficacy and Safety of First-Line Ibrutinib Treatment for Patients with CLL\/SLL: 5 Years of Follow-up from the Phase 3 RESONATE-2 Study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-Term Safety of Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia in 3 Pivotal Studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clml.2016.09.010","article-title":"Risk of Atrial Fibrillation and Bleeding Diathesis Associated with Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials","volume":"17","author":"Yun","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000528019","article-title":"Ibrutinib and Bruton\u2019s Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias\/Sudden Cardiac Death","volume":"68","author":"Boriani","year":"2023","journal-title":"Chemotherapy"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood.2020009617","article-title":"Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia","volume":"137","author":"Byrd","year":"2021","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.2021.278901","article-title":"Cardiovascular Adverse Events in Patients with Chronic Lymphocytic Leukemia Receiving Acalabrutinib Monotherapy: Pooled Analysis of 762 Patients","volume":"107","author":"Brown","year":"2021","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood-2016-12-737346","article-title":"Impact of Ibrutinib Dose Adherence on Therapeutic Efficacy in Patients with Previously Treated CLL\/SLL","volume":"129","author":"Barr","year":"2017","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1080\/10428194.2018.1533129","article-title":"Risk Factors for the Development of Atrial Fibrillation on Ibrutinib Treatment","volume":"60","author":"Lentz","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/hon.2655","article-title":"A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia","volume":"37","author":"Visentin","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/hon.3126","article-title":"Predictors of Ibrutinib-associated Atrial Fibrillation: 5-year Follow-up of a Prospective Study","volume":"41","author":"Mattiello","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of Atrial Fibrillation Adverse Events Reported in Ibrutinib Randomized Controlled Registration Trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1080\/10428194.2017.1375110","article-title":"Cardiac Side Effects of Bruton Tyrosine Kinase (BTK) Inhibitors","volume":"59","author":"Tang","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib Promotes Atrial Fibrillation by Inducing Structural Remodeling and Calcium Dysregulation in the Atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart Rhythm"},{"key":"ref_47","unstructured":"National Comprehensive Cancer Network (2024, March 26). Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (Version 3.2024). Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1478."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/echo.14946","article-title":"Utilizing Left Atrial Strain to Identify Patients at Risk for Atrial Fibrillation on Ibrutinib","volume":"38","author":"Singh","year":"2021","journal-title":"Echocardiography"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing Toxicities of Bruton Tyrosine Kinase Inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","article-title":"Pooled Safety Analysis of Zanubrutinib Monotherapy in Patients with B-Cell Malignancies","volume":"6","author":"Tam","year":"2022","journal-title":"Blood Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative Incidence, Risk Factors, and Management of Atrial Fibrillation in Patients Receiving Ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","article-title":"How I Manage Ibrutinib Intolerance and Complications in Patients with Chronic Lymphocytic Leukemia","volume":"133","author":"Stephens","year":"2019","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00277-015-2566-x","article-title":"How to Choose Appropriate Direct Oral Anticoagulant for Patient with Nonvalvular Atrial Fibrillation","volume":"95","author":"Schaefer","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.7326\/M22-0511","article-title":"Comparative Effectiveness and Safety between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients with Atrial Fibrillation: A Multinational Population-Based Cohort Study","volume":"175","author":"Lau","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e003725","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC Cardio Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/oncolo\/oyac260","article-title":"Managing Ibrutinib-Intolerant Patients with B-Cell Malignancies","volume":"28","author":"Sarosiek","year":"2023","journal-title":"Oncologist"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular Arrhythmias and Sudden Death in Patients Taking Ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1093\/eurheartj\/ehab362","article-title":"Anticancer Drug-Induced Life-Threatening Ventricular Arrhythmias: A World Health Organization Pharmacovigilance Study","volume":"42","author":"Salem","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2022016953","article-title":"Ventricular Arrhythmias and Sudden Death Events Following Acalabrutinib Initiation","volume":"140","author":"Bhat","year":"2022","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jaccao.2020.08.012","article-title":"Acute Effects of Ibrutinib on Ventricular Arrhythmia in Spontaneously Hypertensive Rats","volume":"2","author":"Du","year":"2020","journal-title":"JACC Cardio Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1190099","DOI":"10.3389\/fcvm.2023.1190099","article-title":"Ibrutinib Impairs IGF-1-Dependent Activation of Intracellular Ca Handling in Isolated Mouse Ventricular Myocytes","volume":"10","author":"Tarnowski","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Caldeira, D., Alves, D., Costa, J., Ferreira, J.J., and Pinto, F.J. (2019). Ibrutinib Increases the Risk of Hypertension and Atrial Fibrillation: Systematic Review and Meta-Analysis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0211228"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and Incident Cardiovascular Events Following Ibrutinib Initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-022-01302-7","article-title":"Hypertension and Incident Cardiovascular Events after Next-Generation BTKi Therapy Initiation","volume":"15","author":"Chen","year":"2022","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final Analysis from RESONATE: Up to Six Years of Follow-up on Ibrutinib in Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0735-1097(22)02929-1","article-title":"Myocardial injury after ibrutinib initiation for hematologic malignancies","volume":"79","author":"Buck","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_70","unstructured":"EMA (2024, February 02). IMBRUVICA\u00ae (Ibrutinib): EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imbruvica."},{"key":"ref_71","unstructured":"FDA (2024, February 02). IMBRUVICA\u00ae (Ibrutinib) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/205552s030,210563s006lbl.pdf."},{"key":"ref_72","unstructured":"FDA (2024, February 02). CALQUENCE\u00ae (Acalabrutinib) Precribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/216387Orig2s000Correctedlbl.pdf."},{"key":"ref_73","unstructured":"EMA (2024, February 02). CALQUENCE\u00ae (Acalabrutinib): EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/calquence."},{"key":"ref_74","unstructured":"FDA (2024, February 02). BRUKINSA\u00ae (Zanubrutinib) Prescribing Informations, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213217s007lbl.pdf."},{"key":"ref_75","unstructured":"EMA (2024, February 02). BRUKINSA\u00ae (Zanubrutinib): EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/brukinsa-epar-product-information_en.pdf."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaccao.2023.02.001","article-title":"Ibrutinib Is Associated with Increased Cardiovascular Events and Major Bleeding in Older CLL Patients","volume":"5","author":"Diamond","year":"2023","journal-title":"JACC Cardio Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00059-010-3339-x","article-title":"Proposed Mayo Clinic Criteria for the Diagnosis of Tako-Tsubo Cardiomyopathy and Long-Term Prognosis","volume":"35","author":"Madhavan","year":"2010","journal-title":"Herz"},{"key":"ref_78","first-page":"ytx006","article-title":"Association between Ibrutinib and Mid-Cavitary Takotsubo Cardiomyopathy: A Case Report and a Review of Chemotherapy-Induced Takostubo\u2019s Cardiomyopathy","volume":"1","author":"Giza","year":"2017","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-Year Follow-up of Treatment-Na\u00efve and Previously Treated Patients with CLL and SLL Receiving Single-Agent Ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib Versus Investigator\u2019s Choice in Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results","volume":"6","author":"Ghia","year":"2022","journal-title":"HemaSphere"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed Safety Profile of Acalabrutinib vs Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia in the ELEVATE-RR Trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Wang, L., Zhang, Z., Yu, D., Yang, L., Li, L., He, Y., and Shi, J. (2023). Recent Research of BTK Inhibitors: Methods of Structural Design, Pharmacological Activities, Manmade Derivatives and Structure\u2013Activity Relationship. Bioorg. Chem., 138.","DOI":"10.1016\/j.bioorg.2023.106577"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/bloodadvances.2019000617","article-title":"Oral Bruton Tyrosine Kinase Inhibitors Block Activation of the Platelet Fc Receptor CD32a (Fc\u03b3RIIA): A New Option in HIT?","volume":"3","author":"Goldmann","year":"2019","journal-title":"Blood Adv."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/bloodadvances.2017011999","article-title":"Severe Platelet Dysfunction in NHL Patients Receiving Ibrutinib Is Absent in Patients Receiving Acalabrutinib","volume":"1","author":"Bye","year":"2017","journal-title":"Blood Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3324\/haematol.2018.193391","article-title":"Inhibition of Btk by Btk-Specific Concentrations of Ibrutinib and Acalabrutinib Delays but Does Not Block Platelet Aggregation Mediated by Glycoprotein VI","volume":"103","author":"Nicolson","year":"2018","journal-title":"Haematologica"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1160\/TH16-12-0911","article-title":"Platelet Receptors as Therapeutic Targets: Past, Present and Future","volume":"117","author":"Jamasbi","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.3324\/haematol.2016.155978","article-title":"Effects of Ibrutinib Treatment on Murine Platelet Function during Inflammation and in Primary Hemostasis","volume":"102","author":"Lee","year":"2017","journal-title":"Haematologica"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.15690","article-title":"Incidence of and Risk Factors for Major Haemorrhage in Patients Treated with Ibrutinib: An Integrated Analysis","volume":"184","author":"Brown","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/10428194.2017.1339874","article-title":"Atrial Fibrillation as a Complication of Ibrutinib Therapy: Clinical Features and Challenges of Management","volume":"59","author":"Thorp","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ajh.26788","article-title":"Bruton Tyrosine Kinase Inhibitors in the Management of Waldenstr\u00f6m Macroglobulinemia","volume":"98","author":"Castillo","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1002\/cam4.2998","article-title":"The Impact of Dose Modification and Temporary Interruption of Ibrutinib on Outcomes of Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice","volume":"9","author":"Parikh","year":"2020","journal-title":"Cancer Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/leu.2015.273","article-title":"Incidence and Description of Autoimmune Cytopenias during Treatment with Ibrutinib for Chronic Lymphocytic Leukemia","volume":"30","author":"Rogers","year":"2016","journal-title":"Leukemia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","article-title":"Treatment of Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma with the BTK Inhibitor Zanubrutinib: Phase 2, Single-Arm, Multicenter Study","volume":"13","author":"Xu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia Who Are Intolerant to Ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11899-020-00576-3","article-title":"Management of Ibrutinib Toxicities: A Practical Guide","volume":"15","author":"Lasica","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.3324\/haematol.2020.259432","article-title":"Zanubrutinib Monotherapy for Patients with Treatment-Na\u00efve Chronic Lymphocytic Leukemia and 17p Deletion","volume":"106","author":"Tam","year":"2020","journal-title":"Haematologica"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Estupi\u00f1\u00e1n, H.Y., Bergl\u00f6f, A., Zain, R., and Smith, C.I.E. (2021). Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.630942"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-Line Treatment of Chronic Lymphocytic Leukemia with Ibrutinib plus Obinutuzumab versus Chlorambucil plus Obinutuzumab: Final Analysis of the Randomized, Phase III iLLUMINATE Trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 Trial: Ibrutinib vs Placebo in Treatment-Na\u00efve, Early-Stage Chronic Lymphocytic Leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without Obinutuzumab versus Chlorambucil and Obinutuzumab for Treatment-Naive Chronic Lymphocytic Leukaemia (ELEVATE-TN): A Randomised, Controlled, Phase 3 Trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1007\/s12325-022-02238-7","article-title":"Zanubrutinib Monotherapy for Na\u00efve and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies","volume":"39","author":"Xu","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10875-017-0374-x","article-title":"Gastrointestinal Manifestations in X-Linked Agammaglobulinemia","volume":"37","author":"Barmettler","year":"2017","journal-title":"J. Clin. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41419-021-03702-y","article-title":"Bruton\u2019s Tyrosine Kinase Regulates Gut Immune Homeostasis through Attenuating Th1 Response","volume":"12","author":"Guan","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in Patients with Previously Treated B-Cell Malignancies Intolerant of Previous Bruton Tyrosine Kinase Inhibitors in the USA: A Phase 2, Open-Label, Single-Arm Study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","article-title":"Dermatological Toxicities of Bruton\u2019s Tyrosine Kinase Inhibitors","volume":"21","author":"Sibaud","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.2217\/fon-2016-0180","article-title":"Risk of Severe Rash in Cancer Patients Treated with EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis","volume":"12","author":"Zhang","year":"2016","journal-title":"Future Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of Adverse Effects\/Toxicity of Ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.14302","article-title":"Ibrutinib-associated Rash: A Single-centre Experience of Clinicopathological Features and Management","volume":"180","author":"Iberri","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","article-title":"Incidence and Management of Toxicity Associated with Ibrutinib and Idelalisib: A Practical Approach","volume":"102","author":"Koopmans","year":"2017","journal-title":"Haematologica"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.clml.2020.02.001","article-title":"Ibrutinib-Associated Arthralgias\/Myalgias in Patients with Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes","volume":"20","author":"Rhodes","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1080\/10428194.2022.2038372","article-title":"Characterization of Low-Grade Arthralgia, Myalgia, and Musculoskeletal Pain with Ibrutinib Therapy: Pooled Analysis of Clinical Trials in Patients with Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma","volume":"63","author":"Siddiqi","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3747\/co.27.7009","article-title":"Highlights from ASCO 2020: Updates on the Treatment of Chronic Lymphocytic Leukemia","volume":"27","author":"Dolan","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"563","DOI":"10.6004\/jnccn.2023.5007","article-title":"NCCN Guidelines Update: Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","volume":"21","author":"Stephens","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_117","first-page":"185","article-title":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Wierda","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Carmine Belin, A., Ran, C., and Edvinsson, L. (2020). Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache. Brain Sci., 10.","DOI":"10.3390\/brainsci10010030"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2012-02-414060","article-title":"Decreased Mitochondrial Apoptotic Priming Underlies Stroma-Mediated Treatment Resistance in Chronic Lymphocytic Leukemia","volume":"120","author":"Davids","year":"2012","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of Apoptosis Sensitivity and Resistance to the BH3 Mimetic ABT-737 in Acute Myeloid Leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood-2013-01-475855","article-title":"ABT-199, a New Bcl-2\u2013Specific BH3 Mimetic, Has in Vivo Efficacy against Aggressive Myc-Driven Mouse Lymphomas without Provoking Thrombocytopenia","volume":"121","author":"Vandenberg","year":"2013","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s00277-016-2695-x","article-title":"Effective Mitigation of Tumor Lysis Syndrome with Gradual Venetoclax Dose Ramp, Prophylaxis, and Monitoring in Patients with Chronic Lymphocytic Leukemia","volume":"95","author":"Seymour","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_123","unstructured":"FDA (2024, February 04). VENCLEXTA\u00ae (Venetoclax Tablets) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208573s013lbl.pdf."},{"key":"ref_124","unstructured":"EMA (2024, February 04). Venclyxto: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/venclyxto-epar-product-information_en.pdf."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The Tumor Lysis Syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/hematology.2020000120","article-title":"Preventing and Monitoring for Tumor Lysis Syndrome and Other Toxicities of Venetoclax during Treatment of Chronic Lymphocytic Leukemia","volume":"2020","author":"Fischer","year":"2020","journal-title":"Hematology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"400","DOI":"10.6004\/jadpro.2022.13.4.4","article-title":"Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia","volume":"13","author":"Waggoner","year":"2022","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2021-148696","article-title":"An Observational Study on Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920)","volume":"138","author":"Scarfo","year":"2021","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Fiorcari, S., Brown, W.S., McIntyre, B.W., Estrov, Z., Maffei, R., O\u2019Brien, S., Sivina, M., Hoellenriegel, J., Wierda, W.G., and Keating, M.J. (2013). The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083830"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The Phase 3 DUO Trial: Duvelisib vs Ofatumumab in Relapsed and Refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3324\/haematol.2022.281266","article-title":"PI3K Inhibitors in Chronic Lymphocytic Leukemia: Where Do We Go from Here?","volume":"108","author":"Skanland","year":"2022","journal-title":"Haematologica"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(22)00200-5","article-title":"The Saga of PI3K Inhibitors in Haematological Malignancies: Survival Is the Ultimate Safety Endpoint","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of Adverse Events Associated with Idelalisib Treatment: Expert Panel Opinion","volume":"56","author":"Barrientos","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11899-019-00525-9","article-title":"Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia","volume":"14","author":"Patel","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hon.2540","article-title":"Management of Adverse Events Associated with Idelalisib Treatment in Chronic Lymphocytic Leukemia and Follicular Lymphoma: A Multidisciplinary Position Paper","volume":"37","author":"Cuneo","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 Members after Ibrutinib or Venetoclax Uncover Functional Hierarchy in Determining Resistance to Venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia","volume":"21","author":"Lamothe","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1182\/bloodadvances.2021004861","article-title":"Combined Ibrutinib and Venetoclax Treatment vs Single Agents in the TCL1 Mouse Model of Chronic Lymphocytic Leukemia","volume":"5","author":"Kater","year":"2021","journal-title":"Blood Adv."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-021-00429-z","article-title":"Ibrutinib and Venetoclax Target Distinct Subpopulations of CLL Cells: Implication for Residual Disease Eradication","volume":"11","author":"Lu","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and Venetoclax for First-Line Treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-Duration Ibrutinib plus Venetoclax for First-Line Treatment of CLL: Primary Analysis of the CAPTIVATE FD Cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study","volume":"39","author":"Wierda","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-Duration Ibrutinib\u2013Venetoclax versus Chlorambucil\u2013Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukaemia (GLOW): 4-Year Follow-up from a Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease","volume":"390","author":"Munir","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib Plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S1470-2045(22)00220-0","article-title":"Minimal Residual Disease-Guided Stop and Start of Venetoclax plus Ibrutinib for Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia (HOVON141\/VISION): Primary Analysis of an Open-Label, Randomised, Phase 2 Trial","volume":"23","author":"Kater","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2023-177713","article-title":"First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study","volume":"142","author":"Moreno","year":"2023","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2021-144336","article-title":"Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Na\u00efve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial","volume":"138","author":"Tedeschi","year":"2021","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.2023020013","article-title":"Final Analysis of the CLL2-GIVe Trial: Obinutuzumab, Ibrutinib, and Venetoclax for Untreated CLL with Del(17p)\/TP53 Mut","volume":"142","author":"Huber","year":"2023","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","article-title":"Acalabrutinib, Venetoclax, and Obinutuzumab as Frontline Treatment for Chronic Lymphocytic Leukaemia: A Single-Arm, Open-Label, Phase 2 Study","volume":"22","author":"Davids","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2022-168003","article-title":"Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease","volume":"140","author":"Ryan","year":"2022","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, Obinutuzumab, and Venetoclax with Minimal Residual Disease-Driven Discontinuation in Previously Untreated Patients with Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma: A Multicentre, Single-Arm, Phase 2 Trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1124\/dmd.117.078691","article-title":"Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration between 2013 and 2016","volume":"46","author":"Yu","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cpt.1434","article-title":"Pharmacodynamic Drug\u2013Drug Interactions","volume":"105","author":"Niu","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1080\/10428194.2016.1251592","article-title":"Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL)\/Small Lymphocytic Lymphoma (SLL) in Routine Clinical Practice","volume":"58","author":"Finnes","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cpt.419","article-title":"Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling","volume":"100","author":"Snoeys","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/psp4.12408","article-title":"Evaluation of the Drug\u2013Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP -5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach","volume":"8","author":"Zhou","year":"2019","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"204062072211275","DOI":"10.1177\/20406207221127550","article-title":"Coexisting Conditions and Concomitant Medications Do Not Affect Venetoclax Management and Survival in Chronic Lymphocytic Leukemia","volume":"13","author":"Frustaci","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary Prophylaxis of Invasive Fungal Diseases in Patients with Haematological Malignancies: 2022 Update of the Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"78","author":"Stemler","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.blre.2018.03.004","article-title":"Chronic Lymphocytic Leukemia and Infection Risk in the Era of Targeted Therapies: Linking Mechanisms with Infections","volume":"32","author":"Hilal","year":"2018","journal-title":"Blood Rev."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/17474086.2018.1407645","article-title":"A Review of the Infection Pathogenesis and Prophylaxis Recommendations in Patients with Chronic Lymphocytic Leukemia","volume":"11","author":"Tadmor","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clml.2023.02.001","article-title":"SOHO State of the Art Updates and Next Questions | Infections in Chronic Lymphocytic Leukemia Patients: Risks and Management","volume":"23","author":"Gargiulo","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood-2016-02-702761","article-title":"Idelalisib in the Management of Lymphoma","volume":"128","author":"Cheah","year":"2016","journal-title":"Blood"},{"key":"ref_168","first-page":"821","article-title":"PI3K Inhibitors: Understanding Toxicity Mechanisms and Management","volume":"31","author":"Greenwell","year":"2017","journal-title":"Oncology"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"686768","DOI":"10.3389\/fimmu.2021.686768","article-title":"BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects","volume":"12","author":"Palma","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"E174","DOI":"10.1002\/ajh.25816","article-title":"Second Generation BTK Inhibitors Impair the Anti-fungal Response of Macrophages and Neutrophils","volume":"95","author":"Colado","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ejh.13020","article-title":"Systematic Review of Infectious Events with the Bruton Tyrosine Kinase Inhibitor Ibrutinib in the Treatment of Hematologic Malignancies","volume":"100","author":"Tillman","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clml.2019.10.004","article-title":"Risk of Infection Associated with Ibrutinib in Patients with B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"20","author":"Ball","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/myc.13001","article-title":"Ibrutinib-associated Invasive Fungal Diseases in Patients with Chronic Lymphocytic Leukaemia and non-Hodgkin Lymphoma: An Observational Study","volume":"62","author":"Ruchlemer","year":"2019","journal-title":"Mycoses"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3389\/fimmu.2020.02158","article-title":"BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients with Chronic Lymphocytic Leukemia","volume":"11","author":"Fiorcari","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-Onset Invasive Aspergillosis and Other Fungal Infections in Patients Treated with Ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/10781552231181113","article-title":"Incidence of Invasive Fungal Infections in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib within the Veteran\u2019s Healthcare Administration","volume":"30","author":"Walker","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"e13676","DOI":"10.1111\/myc.13676","article-title":"Invasive Fungal Infection Incidence and Risk Factors in Patients Receiving Ibrutinib in Real-life Settings: A Nationwide Population-based Cohort Study","volume":"67","author":"Allouchery","year":"2023","journal-title":"Mycoses"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1080\/10428194.2020.1775215","article-title":"Incidence and Characterization of Fungal Infections in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib","volume":"61","author":"Frei","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/ciab1026","article-title":"Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors\u2014United States, July 2016\u2013June 2019","volume":"75","author":"Gold","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2016-06-722991","article-title":"Atypical Pneumocystis Jirovecii Pneumonia in Previously Untreated Patients with CLL on Single-Agent Ibrutinib","volume":"128","author":"Ahn","year":"2016","journal-title":"Blood"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"E646","DOI":"10.1002\/ajh.24890","article-title":"Ibrutinib-associated Pneumocystis Jirovecii Pneumonia","volume":"92","author":"Lee","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/bloodadvances.2020001678","article-title":"Pneumocystis Jirovecii Pneumonia and Institutional Prophylaxis Practices in CLL Patients Treated with BTK Inhibitors","volume":"4","author":"Ryan","year":"2020","journal-title":"Blood Adv."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-022-00675-9","article-title":"Pirtobrutinib Inhibits Wild-Type and Mutant Bruton\u2019s Tyrosine Kinase-Mediated Signaling in Chronic Lymphocytic Leukemia","volume":"12","author":"Aslan","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1038\/s41375-021-01252-y","article-title":"Pooled Analysis of Safety Data from Clinical Trials Evaluating Acalabrutinib Monotherapy in Mature B-Cell Malignancies","volume":"35","author":"Furman","year":"2021","journal-title":"Leukemia"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for Patients with Chronic Lymphocytic Leukemia with 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for Chronic Lymphocytic Leukaemia Progressing after Ibrutinib: An Interim Analysis of a Multicentre, Open-Label, Phase 2 Trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for Patients with Chronic Lymphocytic Leukemia Who Progressed during or after Idelalisib Therapy","volume":"131","author":"Coutre","year":"2018","journal-title":"Blood"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(22)00034-5","article-title":"Venetoclax Consolidation after Fixed-Duration Venetoclax plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia (HOVON 139\/GiVe): Primary Endpoint Analysis of a Multicentre, Open-Label, Randomised, Parallel-Group, Phase 2 Trial","volume":"9","author":"Kersting","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1038\/s41375-021-01450-8","article-title":"COVID-19 Severity and Mortality in Patients with CLL: An Update of the International ERIC and Campus CLL Study","volume":"35","author":"Chatzikonstantinou","year":"2021","journal-title":"Leukemia"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/ajh.27093","article-title":"The Evolving Landscape of COVID-19 and post-COVID Condition in Patients with Chronic Lymphocytic Leukemia: A Study by ERIC, the European Research Initiative on CLL","volume":"98","author":"Visentin","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Vitale, C., Boccellato, E., Comba, L., Jones, R., Perutelli, F., Griggio, V., and Coscia, M. (2021). Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia. Cancers, 13.","DOI":"10.3390\/cancers13153856"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the Normal Immune System in Patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.blre.2018.04.007","article-title":"Infections in Patients with Chronic Lymphocytic Leukaemia: Mitigating Risk in the Era of Targeted Therapies","volume":"32","author":"Teh","year":"2018","journal-title":"Blood Rev."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Grywalska, E., Zaborek, M., \u0141yczba, J., Hrynkiewicz, R., B\u0119bnowska, D., Becht, R., Sosnowska-Pasiarska, B., Smok-Kalwat, J., Pasiarski, M., and G\u00f3\u017ad\u017a, S. (2020). Chronic Lymphocytic Leukemia-Induced Humoral Immunosuppression: A Systematic Review. Cells, 9.","DOI":"10.3390\/cells9112398"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00277-024-05625-y","article-title":"Prediction of Severe Infections in Chronic Lymphocytic Leukemia: A Simple Risk Score to Stratify Patients at Diagnosis","volume":"103","author":"Murru","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41467-019-14225-8","article-title":"Machine Learning Can Identify Newly Diagnosed Patients with CLL at High Risk of Infection","volume":"11","author":"Agius","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Mauro, F.R., Giannarelli, D., Visentin, A., Reda, G., Sportoletti, P., Frustaci, A.M., Chiarenza, A., Ciolli, S., Vitale, C., and Laurenti, L. (2021). Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Cancers, 13.","DOI":"10.3390\/cancers13133240"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1182\/blood-2023-188725","article-title":"The Impact of Pausing Bruton Tyrosine Kinase Inhibitor Therapy and Responsiveness of Vaccination in Blood Cancer Patients: Primary Outcome Result for the Randomised Improve Trial","volume":"142","author":"Patten","year":"2023","journal-title":"Blood"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/jha2.724","article-title":"Immune Response to COVID-19 Vaccination in Patients with Waldenstr\u00f6m Macroglobulinaemia Who Pause Their BTKi Therapy","volume":"4","author":"Rankin","year":"2023","journal-title":"eJHaem"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/16078454.2021.1980690","article-title":"Management of Ibrutinib Treatment in Patients with B-Cell Malignancies: Clinical Practice in Portugal and Multidisciplinary Recommendations","volume":"26","author":"Carda","year":"2021","journal-title":"Hematology"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1007\/s10238-023-01244-5","article-title":"Real-Life Diagnostic and Therapeutic Approach to CLL: A 2022 Update from an Expert Panel in Tuscany","volume":"23","author":"Sanna","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/bjh.18075","article-title":"Guideline for the Treatment of Chronic Lymphocytic Leukaemia","volume":"197","author":"Walewska","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab\u2013Cilgavimab) for Prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1135812","DOI":"10.3389\/fonc.2023.1135812","article-title":"An Updated Perspective on Immunoglobulin Replacement in Chronic Lymphocytic Leukaemia in the Era of Targeted Therapies","volume":"13","author":"Khan","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jama.2023.9844","article-title":"Prophylaxis Against Pneumocystis jirovecii Pneumonia in Adults","volume":"330","author":"Zhou","year":"2023","journal-title":"JAMA"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2017-08-764712","article-title":"How I Treat CLL Patients with Ibrutinib","volume":"131","author":"Brown","year":"2018","journal-title":"Blood"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Intracellular Signaling Pathways: Tyrosine Kinase and mTOR Inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/imj.15588","article-title":"Australasian Antifungal Guidelines Steering Committee Consensus Guidelines for Antifungal Prophylaxis in Haematological Malignancy and Haemopoietic Stem Cell Transplantation, 2021","volume":"51","author":"Teh","year":"2021","journal-title":"Intern. Med. J."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3324\/haematol.2018.210252","article-title":"Reactivation of Hepatitis B Virus Infection in Patients with Hematologic Disorders","volume":"104","author":"Wang","year":"2019","journal-title":"Haematologica"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update","volume":"38","author":"Hwang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Tsai, Y.-F., Hsu, C.-M., and Hsiao, H.-H. (2021). Management of Hepatitis B Virus Reactivation in Malignant Lymphoma Prior to Immunosuppressive Treatment. J. Pers. Med., 11.","DOI":"10.3390\/jpm11040267"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2018-01-826495","article-title":"Risk of Hepatitis B Virus Reactivation in Patients Treated with Ibrutinib","volume":"131","author":"Hammond","year":"2018","journal-title":"Blood"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.cmi.2022.02.042","article-title":"Hepatitis B Virus and Hepatitis C Virus Reactivation in Cancer Patients Receiving Novel Anticancer Therapies","volume":"28","author":"Mustafayev","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1080\/10428194.2017.1317094","article-title":"Is HBV Prophylaxis Required during CLL Treatment with Ibrutinib?","volume":"58","author":"Tedeschi","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1080\/10428194.2018.1523401","article-title":"HBV Reactivation in CLL Patients with Occult HBV Infection Treated with Ibrutinib without Viral Prophylaxis","volume":"60","author":"Innocenti","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3324\/haematol.2021.280325","article-title":"Risk of Hepatitis B Virus Reactivation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib with or without Antiviral Prophylaxis. A Retrospective Multicentric GIMEMA Study","volume":"107","author":"Innocenti","year":"2022","journal-title":"Haematologica"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clml.2023.04.006","article-title":"Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors","volume":"23","author":"Chiu","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.3748\/wjg.v29.i33.4942","article-title":"Prevention and Management of Hepatitis B Virus Reactivation in Patients with Hematological Malignancies in the Targeted Therapy Era","volume":"29","author":"Mak","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00277-021-04746-y","article-title":"Management of Herpesvirus Reactivations in Patients with Solid Tumours and Hematologic Malignancies: Update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on Herpes Simplex Virus Type 1, Herpes Simplex Virus Type 2, and Varicella Zoster Virus","volume":"101","author":"Henze","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1080\/10428194.2016.1267352","article-title":"Disseminated Herpes Zoster in Chronic Lymphocytic Leukemia (CLL) Patients Treated with B-Cell Receptor Pathway Inhibitors","volume":"58","author":"Giridhar","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jemermed.2015.10.035","article-title":"Disseminated Herpes Zoster in Chronic Lymphocytic Leukemia","volume":"50","author":"Sutton","year":"2016","journal-title":"J. Emerg. Med."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.idcr.2016.10.003","article-title":"Concurrent Ramsay Hunt Syndrome and Disseminated Herpes Zoster in a Patient with Relapsed Chronic Lymphocytic Leukemia","volume":"6","author":"Chen","year":"2016","journal-title":"IDCases"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamaoncol.2019.3994","article-title":"Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries","volume":"6","author":"Bird","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/hematology.2020000119","article-title":"Managing Toxicities of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors","volume":"2020","author":"Hanlon","year":"2020","journal-title":"Hematology"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjh.15080","article-title":"Optimising Outcomes for Patients with Chronic Lymphocytic Leukaemia on Ibrutinib Therapy: European Recommendations for Clinical Practice","volume":"180","author":"Gribben","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1634\/theoncologist.2020-0388","article-title":"Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia","volume":"25","author":"Hampel","year":"2020","journal-title":"Oncologist"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2016.113","article-title":"Effect of First-Line Treatment on Second Primary Malignancies and Richter\u2019s Transformation in Patients with CLL","volume":"30","author":"Maurer","year":"2016","journal-title":"Leukemia"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41408-019-0237-1","article-title":"Trends in the Risk of Second Primary Malignancies among Survivors of Chronic Lymphocytic Leukemia","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/annonc\/mdw072","article-title":"Incidence and Prognostic Impact of Other Cancers in a Population of Long-Term Survivors of Chronic Lymphocytic Leukemia","volume":"27","author":"Falchi","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","article-title":"Second Cancers in Patients with Chronic Lymphocytic Leukemia Who Received Frontline Fludarabine, Cyclophosphamide and Rituximab Therapy: Distribution and Clinical Outcomes","volume":"56","author":"Benjamini","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1200\/JCO.2002.08.128","article-title":"Therapy-Related Myeloid Leukemias Are Observed in Patients with Chronic Lymphocytic Leukemia After Treatment with Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011","volume":"20","author":"Morrison","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bjh.17337","article-title":"Risk of New Malignancies among Patients with CLL Treated with Chemotherapy: Results of a Danish Population-based Study","volume":"193","author":"Rostgaard","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-023-00784-z","article-title":"Risk of Second Primary Malignancies in Patients with Chronic Lymphocytic Leukemia: A Population-Based Study in the Netherlands, 1989\u20132019","volume":"13","author":"Levin","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"102307","DOI":"10.1016\/j.eclinm.2023.102307","article-title":"Other Malignancies in the History of CLL: An International Multicenter Study Conducted by ERIC, the European Research Initiative on CLL, in HARMONY","volume":"65","author":"Chatzikonstantinou","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic Profiles and 5-Year Results from the Randomized CLL14 Study of Venetoclax plus Obinutuzumab versus Chlorambucil plus Obinutuzumab in Chronic Lymphocytic Leukemia","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2354.2011.01278.x","article-title":"Incurable, Invisible and Inconclusive: Watchful Waiting for Chronic Lymphocytic Leukaemia and Implications for Doctor-Patient Communication: Watchful Waiting for Chronic Lymphocytic Leukaemia","volume":"21","author":"Evans","year":"2012","journal-title":"Eur. J. Cancer Care"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jagp.2017.04.001","article-title":"Cognitive Effects of Chemotherapy and Cancer-Related Treatments in Older Adults","volume":"25","author":"Vega","year":"2017","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/ejh.13503","article-title":"Quality of Life in Patients of Chronic Lymphocytic Leukemia Using the EORTC QLQ-C30 and QLQ-CLL17 Questionnaire","volume":"105","author":"Youron","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"e13678","DOI":"10.1111\/ecc.13678","article-title":"Examining Anxiety and Depression in Haematology Cancer Patients in Ongoing Treatment and under Watchful Waiting: A Systematic Review and Meta-analysis","volume":"31","author":"Russell","year":"2022","journal-title":"Eur. J. Cancer Care"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.20.00491","article-title":"Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Na\u00efve and Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Rogers","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1158\/2159-8290.CD-19-1130","article-title":"Acalabrutinib plus Obinutuzumab in Treatment-Na\u00efve and Relapsed\/Refractory Chronic Lymphocytic Leukemia","volume":"10","author":"Woyach","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Deering, K.L., Sundaram, M., Harshaw, Q., Trudeau, J., and Barrientos, J.C. (2022). Health-Related Quality of Life and Treatment Satisfaction in Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib Compared to Other CLL Treatments in a Real-World US Cross Sectional Study. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0270291"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.clml.2018.08.007","article-title":"Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-Being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","volume":"18","author":"Barrientos","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1080\/10428194.2017.1416364","article-title":"Improvement of Fatigue, Physical Functioning, and Well-Being among Patients with Severe Impairment at Baseline Receiving Ibrutinib in Combination with Bendamustine and Rituximab for Relapsed Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma in the HELIOS Study","volume":"59","author":"Cramer","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1182\/bloodadvances.2021004824","article-title":"Do Age, Fitness, and Concomitant Medications Influence Management and Outcomes of Patients with CLL Treated with Ibrutinib?","volume":"5","author":"Tedeschi","year":"2021","journal-title":"Blood Adv."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2023.03.010","article-title":"Treatment Discontinuation Patterns for Patients with Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study","volume":"23","author":"Shadman","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1200\/JCO.2023.41.16_suppl.7538","article-title":"Ibrutinib Dose Modifications for Management of Cardiac Adverse Events in Patients with B-Cell Malignancies: Pooled Analysis of 10 Clinical Trials","volume":"41","author":"Stephens","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/11\/1996\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:48:05Z","timestamp":1760107685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/11\/1996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":248,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["cancers16111996"],"URL":"https:\/\/doi.org\/10.3390\/cancers16111996","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]}}}